Will 2026 FDA Decisions on Afrezza and FUROSCIX Redefine MannKind’s (MNKD) Narrative
Earlier in January, MannKind Corporation outlined upcoming 2026 regulatory milestones, including FDA decisions on Afrezza label updates, a…
Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever
This drug company offers a decent balance of risk and reward, with a 4.6% yield and a payout…